Background: Generalized Myasthenia gravis (gMG) is a rare autoimmune disease mediated by antibodies- AchR, MuSK, LRP4, etc. While there are multiple medications used to treat gMG, up to 20% of patients are refractory to these treatments resulting in frequent hospitalizations for acute exacerbations, long-lasting side effects from medications, and reduced quality of life. Newer treatment options with novel molecules now focuses on having a more targeted effect, with a higher safety and efficacy profile known to improve disease control. Understanding how these medications work in gMG, the adverse effects, and how to access these treatments are important for nurses who care for these patients.
Methods: Using 3 case studies, the treatment of gMG is discussed to demonstrate the rationale, appropriateness, and potential adverse effects of current and newer treatment options.
Results: While new treatments for gMG are promising, standard therapies such as Pyridostigmine, immune suppressants and modulators, such as prednisone and immunoglobulin, or plasmapheresis remain common treatment options for the majority of gMG patients. Funding for newer treatments challenges most if not all patients to date. Lobbying efforts with government and private insurance companies are ongoing, creating hope for improved MG care.
Conclusions: Generalized Myasthenia gravis remains difficult to treat, yet new treatment options allow patients to embrace the hope that one day there will be a cure for their disease.
